Studies focused on CV safety are available now and results indicate that incretin-based agents have no adverse effect on CV outcomes except saxagliptin increasing risk of heart failure hospitalization [14] and certain GLP-1As have shown CV protective effect [15, 16]. The gene discussed is GCG; the disease is heart failure.